Influence of the 6-month anemia therapy with erythropoietin on renal function and some hemodynamic parameters in predialysis patients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 1-2, 2009, Pages 45-52

  Tomczak Watras, Wirginia ^a   Strózecki, Paweł ^a,c   Zuchora, Zdzisław ^b   Szefer, Jarosław ^b   Manitius, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Prof Franciszek Tukaszczyk Oncology Center   (Poland)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Anemia; Chronic kidney disease (CKD); Erythropoietin; Renal function; Systemic hemodynamics

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEMODIALYSIS PATIENT; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE;

EID: 61349177828     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.602     Document Type: Article

References (40)

1. Stefański A, Shmidt KG, Waldherr R, et al. Early Increase In blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int. 1996; 50:1321-1326.
2. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996; 27: 347-354.
3. Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005; 67: 217-226.
4. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001; 141: 334-341.
5. Greaves SC, Gamble GD, Collins JF, et al. Determinants of left ventricular hyperthrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis. 1994; 24: 768-776.
6. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999; 34:125-134.
7. Tucker B, Fabbian F, Giles M, et al. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant. 1997; 12: 724-728.
8. London GM. Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant. 2001; 16 (Suppl. 2): 3-6.
9. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoetin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000; 35: 250-256.
10. Portoles J, Tarralbo A, Martin P, et al. Cardiovascular effect of recombinant human erythropoetin in predialysis patients. Am J Kidney Dis. 1997; 29: 541-548.
11. Silverberg DS, Blum M, Peer G, et al. Anemia during the predialysis period: a key to cardiac damage in renal failure. Nephron. 1998; 80:1 -5.
12. USRDS: The United States Renal Data System. Am J Kidney Dis. 2003; 42 (Suppl. 5): 1-230.
13. Rutkowski B, Szamotulska K, Dyras P, et al. [Pharmacoeconomical aspects of anemia treatment with different epoetin forms]. Nefrol Dial Pol. 2002; 6:165-169. Polish.
14. Devereux RB, Koren MJ, De Simone G, et al. Methods of detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J. 1993; 14 (Suppl D|: 8-15.
15. The US Recombinant Human Erythropoetin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis. 1991; 18: 50-59.
16. Kang D, Yoon K, Han D. Acute effects of recombinant human erthropoietin on plasma levels of proendothelin-1- and endothelin-1 in hemodialysis patients. Nephrol Dial Transplant. 1998; 13: 2877-2883.
17. Brunkhorst R, Nonnast-Daniel B, Koch K, et al. Hypertension as a possible complication of recombinant human erythropoietin therapy. Contrib Nephrol. 1991; 8: 118-125.
18. Hassan K, Roguin N, Kaganow Y, et al. Effect of erythropoietin therapy on red cells filterability and left ventricular mass in predialysis patients. Ren Fail. 2005; 27:177-182.
19. De Wardener HE, McSwiney RR, Miles BE. Renal haemodynamics in primary policythaemia. Lancet. 1951; 6675: 204-206.
20. Meyers BD, Deen WM, Robertson CR et al. Dynamics of glomerular ultrafiltration in the rat. VIII. Effects of hematocrit. Circ Res. 1975; 36: 425-435.
21. Frenken LA, Wetzels JF, Sluiter HE, et al. Evidence of renal vasodilation in predialysis patients during correction of anemia by erythropoietin. Kidney Int. 1992; 41: 384-387.
22. Lafferty H, Garcia D, Rennke H, et al. Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension. J Am Soc Nephrol. 1991; 1: 1180-1185.
23. Onoyama K, Kumagai H, Shmamatsu K, et al. Effects of human recombinant erythropoietin on anemia, systemic haemodynamics and renal function in predialysis renal failure patients. Nephrol Dial Transplant. 1989; 4: 966-970.
24. Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoetin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001; 16: 307-312.
25. Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoetin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997; 77: 76-185.
26. Abraham PA, Opsahl JA, Rachael KM, et al. Renal function during recombinant human erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol. 1990; 10: 128-136.
27. Rutkowski B, Dȩbska-Ślizień A, Bnło B, et al. Influence of erythropoietin treatment on renal function. Curr Ther Nephrol. 1992, Witching Editore 1993: 207-210.
28. Austrian Multicenter Study of Group rHuEPO in Predialysis Patients. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron. 1992; 61:399-403.
29. Koch KM, Koene RA Messinger D, et al. Use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol. 1995; 44: 201-208.
30. Mitwalli A, Abuaisha H, Wakeel A, et al. Effectiveness of low-dose erythropoietin in predialysis chronic renal failure patients. Nephrol Dial Transplant. 1993; 8:1085-1088.
31. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis. 1994; 24: 777-784.
32. Savica V, Constantino G, Monardo R et al. Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure. Am J Nephrol. 1995; 5: 10-14.
33. Gouwa C, Nikolopoulos P, loannidis JP, et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004; 66: 753-760.
34. Wanic-Kossowska M, Tykarski A, Kobelski M, Czekalski S. [Effectiveness of darbepoietin alfa in anemic patients with chronic kidney disease (CKD) in predialysis period], Pol Arch Med Wewn 2006; 116:663-670. Polish.
35. Wanic-Kossowska M, Tykarski A, Kobelski M, Czekalski S. [Effect of once-weekly subcutaneous darbepoetin a administration on blood pressure, kidney function and quality of live in anemic predialysis patients with chronic kidney disease], Nadciśn Tȩtn. 2007; 11:123-129. Polish.
36. Ismail N, Becker BN. An opportunity to intervene: erythropoietin for the treatment of anemia in preanalysis patients. Nephrol Dial Transplant. 1998; 13:14-17.
37. Furuland H, Linde T, Ahlmen J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003; 18:353-361.
38. Drüeke TB, Locatelli F, Clyne N, et al. for the CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071-2084.
39. Singh AK, Szczech L, Tang KL, et al. for the CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098.
40. Levin A. Understanding recent hemoglobin trials in CKD: methods and lessons learned from CREATE and CHOIR. Nephrol Dial Transplant. 2007; 22: 309-312.